Benjamin Charles, DiogenX CEO
French biotech jumps into type 1 diabetes space with $30M Series A round
France-based biotech DiogenX is gearing up to jump into the race to regenerate beta cells in diabetes patients with the completion of a $30 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
